Drug Duo May Be a Weapon Against a Common Leukemia

The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia (CLL) found that a combination of rituximab and ibrutinib extended patient survival.
Source: WebMD Health - Category: Consumer Health News Source Type: news